Results 261 to 270 of about 33,638 (296)
Folate metabolism in myelofibrosis: a missing key? [PDF]
Ann HematolCerreto GM +8 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Pharmacotherapy of Myelofibrosis
Drugs, 2017Myelofibrosis (MF) is a myeloproliferative neoplasm that is pathologically characterized by bone marrow myeloproliferation, reticulin and collagen fibrosis, and extramedullary hematopoiesis. Constitutive activation of the Janus associated kinase (JAK)-signal transducers and activators of transcription signaling pathway with resultant elevation in pro ...
Douglas Tremblay +2 more
openaire +2 more sources
Myelofibrosis in neuroblastoma
Medical and Pediatric Oncology, 1982AbstractMyelofibrosis, a rare childhood disorder, has been reported as an associated complication of certain hematologic malignancies or as an isolated idiopathic process. In this report, we describe a patient with metastatic neuroblastoma whose initial presentation included the findings of myelofibrosis and leukoery‐throblastosis.
Elaine R. Morgan, Richard J. Labotka
openaire +3 more sources
Hypocholesterolemia in Myelofibrosis
JAMA: The Journal of the American Medical Association, 1981To the Editor.— Gilbert et al ( Blood 54(suppl):84, 1979) reported low serum cholesterol levels in 24 patients with polycythemia vera or myeloid metaplasia. We examined the records of 20 patients who had agnogenic myelofibrosis and myeloid metaplasia. There were 12 men and eight women aged 42 to 94 years (x = 70.5±14.5 SD), all without diseases known
George Spanos +2 more
openaire +3 more sources
Expert Opinion on Pharmacotherapy
Myelofibrosis (MF) is a hematologic disease characterized by bone marrow fibrosis, cytopenias, splenomegaly, and constitutional symptoms. Recent years have seen the emergence of novel therapeutic agents, notably ruxolitinib and fedratinib, which target the Janus kinases (JAK) pathway. However, their myelosuppressive effect coupled with the persistence,
Bruzzese, Antonella +11 more
openaire +2 more sources
Myelofibrosis (MF) is a hematologic disease characterized by bone marrow fibrosis, cytopenias, splenomegaly, and constitutional symptoms. Recent years have seen the emergence of novel therapeutic agents, notably ruxolitinib and fedratinib, which target the Janus kinases (JAK) pathway. However, their myelosuppressive effect coupled with the persistence,
Bruzzese, Antonella +11 more
openaire +2 more sources
Journal of Cutaneous Pathology, 1992
Cutaneous extramedullary hematopoiesis is rare, usually occurring in ueonates following intrauterine viral infections, hereditary spherocytosis or the twin transfusion syndrome. Only 20 cases of cutaneous extramedullary hematopoiesis have been reported in adults, all with myelofibrosis.
D M, Hoss, N S, McNutt
openaire +2 more sources
Cutaneous extramedullary hematopoiesis is rare, usually occurring in ueonates following intrauterine viral infections, hereditary spherocytosis or the twin transfusion syndrome. Only 20 cases of cutaneous extramedullary hematopoiesis have been reported in adults, all with myelofibrosis.
D M, Hoss, N S, McNutt
openaire +2 more sources
Seminars in Hematology, 2005
Idiopathic myelofibrosis (IMF) is characterized by anemia, progressive splenomegaly, bone marrow fibrosis, and extramedullary hematopoiesis. However, patients with a transitional myeloproliferative disorder (MPD), a prefibrotic form of myelofibrosis, or myelofibrosis with a fatty bone marrow share many features of IMF but have clinical characteristics ...
Giovanni, Barosi, Ronald, Hoffman
openaire +2 more sources
Idiopathic myelofibrosis (IMF) is characterized by anemia, progressive splenomegaly, bone marrow fibrosis, and extramedullary hematopoiesis. However, patients with a transitional myeloproliferative disorder (MPD), a prefibrotic form of myelofibrosis, or myelofibrosis with a fatty bone marrow share many features of IMF but have clinical characteristics ...
Giovanni, Barosi, Ronald, Hoffman
openaire +2 more sources